Fulcrum therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., sept. 15, 2023 (globe newswire) -- fulcrum therapeutics, inc.® (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 inducement stock incentive plan, as amended, or the plan, as an inducement material to the new employees entering into employment with fulcrum in accordance with nasdaq listing rule 5635(c)(4).
FULC Ratings Summary
FULC Quant Ranking